- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03738826
Reducing Disparities in Medication Adherence in SLE
July 8, 2021 updated by: Duke University
Reducing Disparities in Medication Adherence of Patients With Systemic Lupus Erythematosus (SLE)
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
135
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- All followup patients seen at the Duke Lupus clinic
Exclusion Criteria
- Patients not seen at the Duke Lupus Clinic
- New patients seen for the first time at the Duke Lupus Clinic
- Patients who are not prescribed any lupus medications
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention arm
Lupus clinic providers will use Surescripts refill information to assess adherence level and address adherence barriers.
We will assess the feasibility and acceptability of the intervention.
|
Lupus clinic providers will be prompted to assess adherence level using Surescripts refill information and address any adherence barriers that arise during the clinical encounter.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility as Measured by Number of Participants With EMR (Electronic Medical Record) Documentation of Adherence
Time Frame: 12 weeks
|
Feasibility as measured by documentation of adherence assessment made by provider.
|
12 weeks
|
Acceptability as Measured by Provider Survey
Time Frame: 12 weeks
|
Acceptability as measured by provider survey, score range 1-5, with a higher score indicating that the intervention was more acceptable.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Adherence as Determined by Self Report
Time Frame: 12 weeks
|
12 weeks
|
|
Percentage of Adherent Participants as Determined by Medication Possession Ratio (MPR)
Time Frame: Baseline, 12 weeks
|
Medication Possession Ratio (MPR) = days with medication/total days.
This will be determined by pharmacy refill data and calculated for 3 months (90 days).
An MPR > or = 80% indicates adherence.
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kai Sun, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 2, 2019
Primary Completion (Actual)
June 7, 2020
Study Completion (Actual)
June 7, 2020
Study Registration Dates
First Submitted
November 6, 2018
First Submitted That Met QC Criteria
November 8, 2018
First Posted (Actual)
November 13, 2018
Study Record Updates
Last Update Posted (Actual)
July 27, 2021
Last Update Submitted That Met QC Criteria
July 8, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00100861
- 5U54MD012530-02 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Behavioral Intervention
-
M.D. Anderson Cancer CenterActive, not recruitingObesity-Related Malignant NeoplasmUnited States
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Brown... and other collaboratorsRecruiting
-
VA Office of Research and DevelopmentCompleted
-
National Taiwan University HospitalUnknown
-
VA Office of Research and DevelopmentRecruiting
-
Pennington Biomedical Research CenterThe Coca-Cola CompanyCompletedParent-targeted Mobile Phone Based Intervention to Increase Physical Activity in Children (P-Mobile)Physical ActivityUnited States
-
University of FloridaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
New York State Psychiatric InstituteCompletedPostpartum DepressionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States